EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC.
EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK+ NSCLC.
J Thorac Dis. 2018 Jun;10(Suppl 17):S1989-S1991
Authors: Christopoulos P, Kirchner M, Endris V, Stenzinger A, Thomas M
PMID: 30023099 [PubMed]
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
More News: Non-Small Cell Lung Cancer